The case for buying the biotech bounce
February 21, 2017 at 08:09 AM EST
Two popular biotech exchange-traded funds have been on a tear lately, and some strategists see more upside ahead.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.